Clinical Trial: Chidamide Plus CHOP Improve the Survival of Newly Diagnosed Angioimmunoblastic T-cell Lymphoma

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2024 Sep 4

PMID 39229263

Authors

Xiangping Zong

Zhen Yang

Jin Zhou

Zhengming Jin

Depei Wu

Affiliations

Soon will be listed here.

Abstract

Background: Angioimmunoblastic T-cell lymphoma (AITL) is known for its unfavorable survival prognosis. Chidamide has shown efficacy in relapsed/refractory AITL, but its efficacy in newly diagnosed AITL is uncertain.

Objective: This retrospective research aimed to evaluate the effectiveness and safety of chidamide when used with doxorubicin, cyclophosphamide, prednisone, and vincristine (CHOP) in comparison to CHOP by itself for individuals newly diagnosed with AITL, and to examine the impact of transplantation.

Method: This was an analysis that compared outcomes among patients who received chidamide + CHOP on a clinical trial vs. historical controls who received CHOP alone, enrolling a total of sixty-six treatment-naive AITL patients between April 2014 and November 2022. Among them, thirty-three received chidamide in addition to CHOP (chidamide group), while thirty-three received CHOP alone (control group). The clinical characteristics were balanced between the two groups. All patients were scheduled to undergo up to six courses of treatment before transplantation.

Results: The chidamide group had a significantly longer median overall survival (OS) compared to the control group, with a median OS that was not reached, as opposed to 20 months in the control group (p = 0.002). In the control group, the median progression-free survival (PFS) was 11 months, while in the chidamide group, it was 22 months (p = 0.080). In the high-risk group (IPI ≥ 3), the chidamide group demonstrated notably superior complete response (CR) and overall response rate (ORR) compared to the control cohort (p = 0.002, p = 0.034). The PFS and OS in the chidamide group were not reached, and there were significant differences compared to the control group (p = 0.007, p = 0.003). The median OS of the transplanted group was longer than the non-transplanted group (p = 0.004). On multivariate analysis, chidamide group reduced the hazards of death in the total cohort.

Conclusion: As the study was non-random and retrospective, Chidamide combined with chemotherapy should be tested in randomized trials given its potential to improve prognosis in treatment-naive AITL patients. Furthermore, autologous hematopoietic stem cell transplantation (auto-HSCT) has demonstrated enhanced overall survival in individuals with AITL.

Clinical Trial Registration: https://clinicaltrials.gov/, NCT03268889.

References

Yao W, Wu F, Zhang W, Chuang S, Thompson J, Chen Z . Angioimmunoblastic T-cell lymphoma contains multiple clonal T-cell populations derived from a common TET2 mutant progenitor cell. J Pathol. 2019; 250(3):346-357. PMC: 7064999. DOI: 10.1002/path.5376. View

Rai S, Kim W, Ando K, Choi I, Izutsu K, Tsukamoto N . Oral HDAC inhibitor tucidinostat in patients with relapsed or refractory peripheral T-cell lymphoma: phase IIb results. Haematologica. 2022; 108(3):811-821. PMC: 9973490. DOI: 10.3324/haematol.2022.280996. View

Bachy E, Camus V, Thieblemont C, Sibon D, Casasnovas R, Ysebaert L . Romidepsin Plus CHOP Versus CHOP in Patients With Previously Untreated Peripheral T-Cell Lymphoma: Results of the Ro-CHOP Phase III Study (Conducted by LYSA). J Clin Oncol. 2021; 40(3):242-251. DOI: 10.1200/JCO.21.01815. View

Vose J, Armitage J, Weisenburger D . International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol. 2008; 26(25):4124-30. DOI: 10.1200/JCO.2008.16.4558. View

Moskowitz A . Practical Treatment Approach for Angioimmunoblastic T-Cell Lymphoma. J Oncol Pract. 2019; 15(3):137-143. PMC: 7850668. DOI: 10.1200/JOP.18.00511. View

. Falchi L, Ma H, Klein S, et al. Combined oral 5-azacytidine and romidepsin are highly effective in patients with PTCL: a multicenter phase 2 study. Blood. 2021;137(16):2161-2170. Blood. 2022; 139(10):1600. DOI: 10.1182/blood.2021012550. View

Ong S, Zain J . Aggressive T-cell lymphomas: 2024: Updates on diagnosis, risk stratification, and management. Am J Hematol. 2024; 99(3):439-456. DOI: 10.1002/ajh.27165. View

Chang E, Yang V, Ong S, Kang H, Lim B, De Mel S . Clinical features and prognostic outcomes of angioimmunoblastic T cell lymphoma in an Asian multicenter study. Leuk Lymphoma. 2023; 64(11):1782-1791. DOI: 10.1080/10428194.2023.2235043. View

Wang J, Su N, Fang Y, Ma S, Zhang Y, Cai J . Comparison of Chemotherapy Combined With Chidamide Versus Chemotherapy in the Frontline Treatment for Peripheral T-Cell Lymphoma. Front Immunol. 2022; 13:835103. PMC: 8847145. DOI: 10.3389/fimmu.2022.835103. View

10.

Cao H, Li L, Xue S, Dai H . Chidamide: Targeting epigenetic regulation in the treatment of hematological malignancy. Hematol Oncol. 2022; 41(3):301-309. DOI: 10.1002/hon.3088. View

11.

DAmore F, Relander T, Lauritzsen G, Jantunen E, Hagberg H, Anderson H . Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01. J Clin Oncol. 2012; 30(25):3093-9. DOI: 10.1200/JCO.2011.40.2719. View

12.

Chiba S, Sakata-Yanagimoto M . Advances in understanding of angioimmunoblastic T-cell lymphoma. Leukemia. 2020; 34(10):2592-2606. PMC: 7376827. DOI: 10.1038/s41375-020-0990-y. View

13.

Lage L, Culler H, Reichert C, da Siqueira S, Pereira J . Angioimmunoblastic T-cell lymphoma and correlated neoplasms with T-cell follicular helper phenotype: from molecular mechanisms to therapeutic advances. Front Oncol. 2023; 13:1177590. PMC: 10169672. DOI: 10.3389/fonc.2023.1177590. View

14.

Kameda K, Kako S, Kim S, Usui Y, Kato K, Fukuda T . Autologous or allogeneic hematopoietic cell transplantation for relapsed or refractory PTCL-NOS or AITL. Leukemia. 2022; 36(5):1361-1370. DOI: 10.1038/s41375-022-01545-w. View

15.

Chiappella A, Dodero A, Evangelista A, Re A, Orsucci L, Usai S . Romidepsin-CHOEP followed by high-dose chemotherapy and stem-cell transplantation in untreated Peripheral T-Cell Lymphoma: results of the PTCL13 phase Ib/II study. Leukemia. 2023; 37(2):433-440. PMC: 9898022. DOI: 10.1038/s41375-022-01780-1. View

16.

Swerdlow S, Campo E, Pileri S, Lee Harris N, Stein H, Siebert R . The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016; 127(20):2375-90. PMC: 4874220. DOI: 10.1182/blood-2016-01-643569. View

17.

Kyriakou C, Canals C, Goldstone A, Caballero D, Metzner B, Kobbe G . High-dose therapy and autologous stem-cell transplantation in angioimmunoblastic lymphoma: complete remission at transplantation is the major determinant of Outcome-Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol. 2008; 26(2):218-24. DOI: 10.1200/JCO.2008.12.6219. View

18.

Zhang Q, Yin L, Lai Q, Zhao Y, Peng H . Advances in the pathogenesis and therapeutic strategies of angioimmunoblastic T-cell lymphoma. Clin Exp Med. 2023; 23(8):4219-4235. DOI: 10.1007/s10238-023-01197-9. View

19.

Lu G, Jin S, Lin S, Gong Y, Zhang L, Yang J . Update on histone deacetylase inhibitors in peripheral T-cell lymphoma (PTCL). Clin Epigenetics. 2023; 15(1):124. PMC: 10398948. DOI: 10.1186/s13148-023-01531-8. View

20.

Shi Y, Dong M, Hong X, Zhang W, Feng J, Zhu J . Results from a multicenter, open-label, pivotal phase II study of chidamide in relapsed or refractory peripheral T-cell lymphoma. Ann Oncol. 2015; 26(8):1766-71. DOI: 10.1093/annonc/mdv237. View